Novartis scores its latest FDA OK — this time for a new sickle cell disease drug picked up in a $665M deal
Novartis’ decision to buy Oklahoma-based biotech Selexys 3 years ago for up to $665 million has paid off with an FDA approval today.
Blessed with the FDA’s breakthrough drug designation for a speedy review, the pharma giant has pinned down an approval for crizanlizumab, a new therapy designed to reduce the frequency of painful incidents of vaso-occlusive crises among sickle cell disease patients 16 or older.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 102,400+ biopharma pros reading Endpoints daily — and it's free.